Orelabrutinib for early-stage untreated marginal zone lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an oral targeted therapy (orelabrutinib) for people with early-stage marginal zone lymphoma who have not yet had treatment. The goal is to see if this medication can control the cancer with fewer side effects than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with marginal zone lymphoma that is stage I or II (early stage, not widespread).
- Your physical function is good enough to be up and about at least half the day (ECOG score 0-2).
- Your blood counts, liver, and kidney function are within a safe range (specific levels will be checked by the doctor).
- You do not have serious heart problems, active bleeding, or a history of blood clots in the past six months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, orelabrutinib and obinutuzumab, for people with a type of slow-growing lymphoma called marginal zone lymphoma who have not had any previous treatment. The goal is to see if this combination can shrink or control the cancer with manageable side effects.
This trial tests a combination of two targeted drugs (orelabrutinib and obinutuzumab) as a first treatment for marginal zone lymphoma that has returned or progressed after local therapy. The goal is to see if this combination works better than current options.
This trial tests a combination of two targeted therapies—oralebrutinib (a pill that blocks a protein in cancer cells) and rituximab (an antibody infusion)—for people with marginal zone lymphoma that has returned or cannot be treated with local therapies. The goal is to see if this combo works well and is safe.
This trial tests a combination of targeted therapy (orelabrutinib) plus chemotherapy (BR) or antibody therapy (G) for people with untreated marginal zone lymphoma. It aims to see if this combination can help patients who haven't had treatment yet.
This study tests a combination of three drugs—orelabrutinib, obinutuzumab, and lenalidomide—as a first treatment for marginal zone lymphoma. The goal is to see if this mix of targeted therapies works well and safely.
This Phase 2 study tests whether orelabrutinib combined with rituximab, followed by orelabrutinib alone for a while, can control follicular lymphoma that has come back or did not respond. It may help shrink tumors and keep the disease from worsening after initial response.
Hear when a new Marginal Zone Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.